Table 3.

High-frequency Keywords in the TNBC Study.

Rank	Keywords	Frequency, n	Percentage, %	Cumulative Percentage, %
1	Triple negative breast cancer	3044	10.0	10.0
2	Breast cancer	1842	6.08	16.1
3	Prognosis	421	1.39	17.5
4	Triple negative	351	1.16	18.7
5	Apoptosis	339	1.12	19.8
6	Metastasis	315	1.04	20.8
7	Epithelial-mesenchymal transition	195	0.64	21.5
8	Chemotherapy	189	0.62	22.1
9	Biomarker	150	0.49	22.6
10	Immunotherapy	149	0.49	23.1
11	Neoadjuvant chemotherapy	144	0.48	23.6
12	Brca1	127	0.42	24.0
13	Survival	124	0.41	24.4
14	Immunohistochemistry	121	0.40	24.8
15	Invasion	120	0.40	25.2
16	Targeted therapy	120	0.40	25.6
17	Egfr	117	0.39	26.0
18	Proliferation	101	0.33	26.3
19	Migration	95	0.31	26.6
20	Cancer	92	0.300	26.9
21	Estrogen receptor	90	0.30	27.2
22	HER2	89	0.29	27.5
23	Autophagy	89	0.29	27.8
24	Molecular subtype	86	0.28	28.1
25	Androgen receptor	80	0.26	28.3
26	Cancer stem cells	79	0.26	28.6
27	PD-L1	76	0.25	28.9
28	Angiogenesis	76	0.25	29.1
29	MDA-MB-231	70	0.23	29.3
30	Breast neoplasms	70	0.23	29.6
31	MicroRNA	69	0.23	29.8
32	Doxorubicin	69	0.23	30.0
33	Paclitaxel	69	0.23	30.2
34	PARP inhibitor	66	0.22	30.5
35	Metastatic breast cancer	65	0.21	30.7
36	Pathological complete response	65	0.21	30.9
37	Cisplatin	65	0.21	31.1
38	Cell cycle	63	0.21	31.3
39	Akt	62	0.20	31.5
40	Tumor-infiltrating lymphocyte	62	0.20	31.7
41	Overall survival	58	0.19	31.9
42	Brain metastases	58	0.19	32.1
43	P53	57	0.19	32.3
44	Stat3	56	0.18	32.5
45	Breast	55	0.18	32.7
46	Tumor microenvironment	53	0.17	32.8
47	Drug resistance	52	0.17	33.0
48	Basal-like breast cancer	51	0.17	33.2
49	Cancer stem cells	51	0.17	33.3
50	Triple negative breast neoplasms	50	0.17	33.5